However, tumor suppressors (and their downstream pathways) are increasingly regarded as potentially powerful therapeutic targets [110], particularly if a definite structure such as a pocket can be identified, as exemplified by molecules blocking the interaction of p53 with MDM2 thus increasing wild-type p53 [111]. Here, MDM2 is linked to neoplasm.